Clinical and demographic characteristics of patients with multiple sclerosis

Main Article Content

Brenda Bertado-Cortés
Lyda Villamil-Osorio
Raúl Carrera-Pineda
Carlos Martínez-Cortés
José Guerrero-Cantera

Keywords

Multiple sclerosis, Epidemiology

Abstract

Background: Multiple sclerosis (MS) is a disease whose physiopathogenesis shows a complex interaction of genetic and environmental factors. Given that those factors have not been documented in our country, we describe the clinical and demographic characteristics from a sample of patients with MS.

Methods: We carried out an observational, descriptive, cross-sectional, and retrolective study in a Center for Demyelinating Diseases. We took the information from the clinical records of a sample of patients with multiple sclerosis, who arrived to the center from April 2014 to July 2015.

Results: We obtained data from 313 patients, out of which 65.5 % were women. Mean age was 41 years (SD 11.22). Minimum age of diagnosis was 12 years and maximum, 66 years; mean age of diagnosis was 32 years (SD 9.72). With regards to clinical variables, 3.4 % presented radiologically isolated syndrome (RIS), 82 % relapsing-remitting MS (RRMS), 13.9 % secondary-progressive MS (SPMS), and 0.8 % primary-progressive MS (PPMS). Of all the patients, 10 % had first or second degree relatives with diagnosis of this disease; 16 % had foreign ancestors; 27 % were smokers. Treatment consisted of glatiramer acetate, 28 %; intramuscular interferon beta 1a, 18 %; subcutaneous interferon beta 1a, 16 %; subcutaneous interferon beta 1b, 30 %; fingolimod, 3 %; and others, 5 %.

Conclusions: Clinical and demographic characteristics are similar to those reported in international literature. More studies would be needed to typify Mexican population with MS.

Abstract 4746 | PDF (Spanish) Downloads 301 HTML (Spanish) Downloads 6299 PubMed (Spanish) Downloads 0 HTML Downloads 191

References

Hartung HP, Aktas O, Menge T, Kieseier B. Multiple Sclerosis and Related Disorders: Immune regulation of multiple sclerosis. Handb Clin Neurol. 2014;122:3-14. doi: 10.1016/B978-0-444-52001-2.00001-7.

 

Compston A, Coles A. Multiple sclerosis. Lancet. 2008 Oct 25;372(9648):1502-17. doi: 10.1016/S0140-6736(08)61620-7.

 

Ramagopalan S, Dobson R, Meier U, Giovannoni G. Multiple sclerosis: risk factors, prodromes, and potential causal pathways. Lancet Neurol. 2010 Jul;9(7):727-39. doi: 10.1016/S1474-4422(10)70094-6.

 

Simpson S, Taylor B, Van Der Mei I. The role of epidemiology in MS research: Past successes, current challenges and future potential. Mult Scler. 2015 Jul;21(8):969-77. doi: 10.1177/1352458515574896.

 

Multiple Sclerosis International Federation. Atlas of Multiple Sclerosis 2013: Mapping Multiple Sclerosis Around the World. London: Multiple Sclerosis International Federation; 2013. Disponible en http://www.msif.org/about-ms/publications-and-resources/

 

Corona T, Flores J. Esclerosis Múltiple (EM) en América Latina. Revista Española de Esclerosis Múltiple. 2009;12:5-8.

 

Torkildsen Ø, Aarseth J, Benjaminsen E, Celius E, Holmøy T. Month of birth and risk of multiple sclerosis: confounding and adjustments. Ann Clin Transl Neurol. 2014 Feb; 1(2):141-4. doi: 10.1002/acn3.37

 

Staples J, Ponsonby AL, Lim L. Low maternal exposure to ultraviolet radiation in pregnancy, month of birth, and risk of multiple sclerosis in offspring: longitudinal analysis. BMJ. 2010;340:c1640.

 

Marrie RA. Demographic, Genetic, and Environmental Factors That Modify Disease Course. Neurol Clin. 2011 May;29(2):323-41. doi: 10.1016/j.ncl.2010.12.004.

 

Rice G. The genetic epidemiology of multiple sclerosis. Continuum: Lifelong Learning in Neurology. 2004;10(6):28-37.

 

Shirani A, Tremlett H. The effect of smoking on the symptoms and progression of multiple sclerosis: a review. J Inflamm Res. 2010;3:115-26.